Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMM5208)

Drug Name

Oxindole 16 (compound 3) Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Preclinical Drug(s)

Investigative Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Cyclin-dependent kinase 8 (CDK8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SEL120	DMHCUZV	Acute myeloid leukaemia	2A60	Phase 1	[2]
Tricyclic benzimidazole derivative 1	DM5SD9E	N. A.	N. A.	Patented	[3]
Macrocycle derivative 14	DMXSRPH	N. A.	N. A.	Patented	[3]
CCT251545	DMNA9KW	Colorectal cancer	2B91.Z	Preclinical	[4]
Oxindole 94	DMPFD6Y	Pain	MG30-MG3Z	Investigative	[1]
------------------------------------------------------------------------------------

Drug(s) Targeting Cyclin-dependent kinase 5 (CDK5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
KENPAULLONE	DMAGVXW	Discovery agent	N.A.	Patented	[5]
Roscovitine derivative 1	DMD1G3Z	N. A.	N. A.	Patented	[3]
Tricyclic benzimidazole derivative 1	DM5SD9E	N. A.	N. A.	Patented	[3]
4-(thiazol-5-yl)-pyrimidine derivative 2	DMMQFCN	N. A.	N. A.	Patented	[3]
Pyrazolo[1,5-a]-1,3,5-triazine derivative 1	DMOK7CW	N. A.	N. A.	Patented	[3]
Naphthyridine and isoquinoline derivative 1	DMTGIP7	N. A.	N. A.	Patented	[3]
PMID26161698-Compound-18	DM6JVR5	N. A.	N. A.	Patented	[3]
Flavonoid derivative 7	DM6A9UR	N. A.	N. A.	Patented	[3]
L-751250	DMOERXK	Obesity	5B81	Preclinical	[1]
Olomoucine	DMNAFG1	N. A.	N. A.	Terminated	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25.
2	Clinical pipeline report, company report or official report of Ryvu Therapeutics.
3	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
4	Kinase inhibitors: the road ahead. Nat Rev Drug Discov. 2018 May;17(5):353-377.
5	1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6.